Your browser doesn't support javascript.
loading
Early prediction of renal graft function: Analysis of a multi-center, multi-level data set.
Blazquez-Navarro, Arturo; Bauer, Chris; Wittenbrink, Nicole; Wolk, Kerstin; Sabat, Robert; Dang-Heine, Chantip; Neumann, Sindy; Roch, Toralf; Wehler, Patrizia; Blazquez-Navarro, Rodrigo; Olek, Sven; Thomusch, Oliver; Seitz, Harald; Reinke, Petra; Hugo, Christian; Sawitzki, Birgit; Babel, Nina; Or-Guil, Michal.
Afiliación
  • Blazquez-Navarro A; Systems Immunology Lab, Department of Biology, Humboldt-Universität zu Berlin: Philippstr. 13, 10115 Berlin, Germany; Berlin Institute of Health (BIH), Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin: Augustenburger Platz 1, 13353 Berlin, Germany; Center for Transl
  • Bauer C; MicroDiscovery GmbH: Marienburger Str. 1, 10405 Berlin Germany.
  • Wittenbrink N; Systems Immunology Lab, Department of Biology, Humboldt-Universität zu Berlin: Philippstr. 13, 10115 Berlin, Germany; Berlin Institute of Health (BIH), Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin: Augustenburger Platz 1, 13353 Berlin, Germany.
  • Wolk K; Berlin Institute of Health (BIH), Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin: Augustenburger Platz 1, 13353 Berlin, Germany; Psoriasis Research and Treatment Center, Institute of Medical Immunology/Department of Dermatology and Allergy, Charité - Universitätsm
  • Sabat R; Psoriasis Research and Treatment Center, Institute of Medical Immunology/Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin: Charitéplatz 1, 10117 Berlin, Germany; Interdisciplinary Group of Molecular Immunopathology, Institute of Medical Immunology/Department of Dermatology
  • Dang-Heine C; Berlin Institute of Health (BIH), Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin: Augustenburger Platz 1, 13353 Berlin, Germany; Clinical Study Center (CSC), Berlin Institute of Health, and Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universitä
  • Neumann S; numares AG: Am Biopark 9, 93053 Regensburg, Germany.
  • Roch T; Berlin Institute of Health (BIH), Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin: Augustenburger Platz 1, 13353 Berlin, Germany; Center for Translational Medicine, Universitätsklinikum der Ruhr-Universität Bochum, Medizinische Klinik I: Hölkeskampring 40, 44625 He
  • Wehler P; Berlin Institute of Health (BIH), Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin: Augustenburger Platz 1, 13353 Berlin, Germany; Center for Translational Medicine, Universitätsklinikum der Ruhr-Universität Bochum, Medizinische Klinik I: Hölkeskampring 40, 44625 He
  • Blazquez-Navarro R; Systems Immunology Lab, Department of Biology, Humboldt-Universität zu Berlin: Philippstr. 13, 10115 Berlin, Germany.
  • Olek S; Ivana Türbachova Laboratory for Epigenetics, Epiontis GmbH, Precision for Medicine Group: Barbara-McClintock-Straße 6, 12489 Berlin, Germany.
  • Thomusch O; Klinik für Allgemein- und Viszeralchirurgie, Universitätsklinikum Freiburg: Hugstetter Straße 55, 79106 Freiburg, Germany.
  • Seitz H; Fraunhofer Institute for Cell Therapy and Immunology, Bioanalytics und Bioprocesses: Am Mühlenberg 13, 14476 Potsdam-Golm, Germany.
  • Reinke P; Berlin Institute of Health (BIH), Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin: Augustenburger Platz 1, 13353 Berlin, Germany; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin: Augustenburger Platz 1, 13353 Berlin, Germany.
  • Hugo C; Universitätsklinikum Carl Gustav Carus, Medizinische Klinik III - Bereich Nephrologie: Fetscherstraße 74, 01307 Dresden, Germany.
  • Sawitzki B; Berlin Institute of Health (BIH), Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin: Augustenburger Platz 1, 13353 Berlin, Germany.
  • Babel N; Berlin Institute of Health (BIH), Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin: Augustenburger Platz 1, 13353 Berlin, Germany; Center for Translational Medicine, Universitätsklinikum der Ruhr-Universität Bochum, Medizinische Klinik I: Hölkeskampring 40, 44625 He
  • Or-Guil M; Systems Immunology Lab, Department of Biology, Humboldt-Universität zu Berlin: Philippstr. 13, 10115 Berlin, Germany; Institute of Medical Immunology, Charité - Universitätsmedizin Berlin: Charitéplatz 1, 10117 Berlin, Germany. Electronic address: michal.or-guil@charite.de.
Curr Res Transl Med ; 70(3): 103334, 2022 07.
Article en En | MEDLINE | ID: mdl-35193070
ABSTRACT
PURPOSE OF THE STUDY Long-term graft survival rates after renal transplantation are still poor. We aimed to build an early predictor of an established long-term outcomes marker, the estimated glomerular filtration rate (eGFR) one year post-transplant (eGFR-1y). MATERIALS AND

METHODS:

A large cohort of 376 patients was characterized for a multi-level bio-marker panel including gene expression, cytokines, metabolomics and antibody reactivity profiles. Almost one thousand samples from the pre-transplant and early post-transplant period were analysed and employed for machine learning-assisted prediction.

RESULTS:

Pre-transplant data led to a prediction achieving a Pearson's correlation coefficient of r=0.38 between measured and predicted eGFR-1y. Two weeks post-transplant, the correlation was improved to r=0.63, and at the third month, to r=0.76. eGFR values were stable throughout the first post-transplant year. Several characteristics were predictive for eGFR, including age of donor and recipient, body mass index, HLA mismatch, cytomegalovirus mismatch and valganciclovir prophylaxis. Additionally, a subset of 19 nuclear magnetic resonance bins of the urine metabolome data was shown to have potential applications in non-invasive eGFR monitoring. Importantly, we identified the expression of the genes TMEM176B and HMMR as potential prognostic markers for changes in the eGFR after the second post-transplantation week.

CONCLUSIONS:

Our multi-center, multi-level data set represents a milestone in the efforts to predict transplant outcome. While an acceptable predictive capacity was achieved, we are still far from predicting changes in the eGFR precisely. Additional studies employing further marker panels are needed to establish predictors of eGFR-1y for clinical application; herein, gene expression markers seem to hold the most promise.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Trasplante de Riñón Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Curr Res Transl Med Año: 2022 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Trasplante de Riñón Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Curr Res Transl Med Año: 2022 Tipo del documento: Article